Frontier Biotechnologies Gets Nod to Trial Kidney Disease Drug

MT Newswires Live

01/02

Frontier Biotechnologies (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.

FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).

The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.

Citing data from Frost & Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.

The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2600703797"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2600703797\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2600703797?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-02 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600703797","market":"us","top_or_hot":-1,"title":"Frontier Biotechnologies Gets Nod to Trial Kidney Disease Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/688221\">Frontier Biotechnologies</a> (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.</p><p>FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).</p><p>The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.</p><p>Citing data from Frost &amp; Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.</p><p>The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Frontier Biotechnologies Gets Nod to Trial Kidney Disease Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrontier Biotechnologies Gets Nod to Trial Kidney Disease Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-02 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/688221\">Frontier Biotechnologies</a> (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.</p><p>FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).</p><p>The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.</p><p>Citing data from Frost &amp; Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.</p><p>The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FTR","symbol_name":"Frontier通信B系列","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2600703797","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600703797","pubTimestamp":1767317521,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Frontier Biotechnologies  has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy .The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.Citing data from Frost & Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688221":"前沿生物","FTR":"Frontier通信B系列","BK0239":"医药制造"},"translate_title":"Frontier Biotechnologies获得肾病药物试验许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688221":0.9,"FTR":1.5},"content_text":"Frontier Biotechnologies (SHA:688221) has obtained approval from China's National Medical Products Administration to carry out a clinical trial of its FB7013 injection, according to a Thursday filing with the Shanghai Stock Exchange.FB7013 is a siRNA drug indicated to reduce kidney tissue damage for patients with immunoglobulin A nephropathy (IgA nephropathy).The company said it can be expanded to multiple areas of diseases related to membranous nephropathy and diabetic nephropathy.Citing data from Frost & Sullivan, Frontier said the number of patients with IgA globally increased to 9.3 million in 2020 from 8.8 million in 2015, and is forecast to reach 10.2 million by 2030.The global market for nephropathy treatments is estimated to have reached $1.2 billion in 2025 from $567 million in 2020, representing a 16.1% CAGR, Frontier added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}